Replies to post #363 on Rockwell Medical Technologies, Inc. (RMTI)

[BlazingStocks]

Looking forward to seeing the results...$RMTI

“This is an important step for Rockwell Medical and home infusion patients as we believe that FPC is uniquely suited to address this important unmet clinical need,” said Russell Ellison, M.D., President and Chief Executive Officer of Rockwell Medical. “We expect to finalize our Phase 2 clinical study design and protocol with the advice and guidance of the FDA.”

[ProfitScout]

RTMI is making important advances for the better treatment of anemia which affects millions of people around the world as a result of iron deficiency. The latest news here on the company's progress for clinical trials is very encouraging.

Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. The Company is developing FPC for the treatment of iron deficiency in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting, a large and rapidly growing segment of healthcare, and where these patients suffer from chronic diseases associated with high incidence of iron deficiency and anemia. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States.

For more information, visit http://www.RockwellMed.com.

[BlazingStocks]

I found this page of the website interesting and informative, to help me understand why this technology is so special.

https://www.rockwellmed.com/our-technology/technology-platform/

PLATFORM TECHNOLOGY TO MANAGE IRON IN A NEW WAY
Ferric pyrophosphate citrate (FPC) is a novel complex iron salt, developed to replace iron losses in patients with anemia in an entirely new way. This unique and differentiated molecule consists of an iron atom complexed to one pyrophosphate and two citrate anions. This formulation has been shown to allow for rapid donation of iron to transferrin, protein in the blood that binds to iron and transports it through the body, including to the bone marrow. This mechanism uses the body’s own means to transport iron safely to tissues that need iron (i.e. red blood cells and muscle).